RLAY vs. MESO, PRME, RGNX, CRGX, HUMA, PROK, IMTX, KYTX, HLVX, and AUTL
Should you be buying Relay Therapeutics stock or one of its competitors? The main competitors of Relay Therapeutics include Mesoblast (MESO), Prime Medicine (PRME), REGENXBIO (RGNX), CARGO Therapeutics (CRGX), Humacyte (HUMA), ProKidney (PROK), Immatics (IMTX), Kyverna Therapeutics (KYTX), HilleVax (HLVX), and Autolus Therapeutics (AUTL). These companies are all part of the "biological products, except diagnostic" industry.
Mesoblast (NASDAQ:MESO) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
Mesoblast received 364 more outperform votes than Relay Therapeutics when rated by MarketBeat users. Likewise, 70.45% of users gave Mesoblast an outperform vote while only 60.94% of users gave Relay Therapeutics an outperform vote.
Mesoblast has a net margin of 0.00% compared to Mesoblast's net margin of -1,263.49%. Relay Therapeutics' return on equity of 0.00% beat Mesoblast's return on equity.
Mesoblast has higher earnings, but lower revenue than Relay Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Mesoblast has a beta of 3.45, meaning that its stock price is 245% more volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.
1.4% of Mesoblast shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 4.3% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Mesoblast had 2 more articles in the media than Relay Therapeutics. MarketBeat recorded 4 mentions for Mesoblast and 2 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 0.35 beat Mesoblast's score of -0.19 indicating that Mesoblast is being referred to more favorably in the media.
Mesoblast presently has a consensus price target of $13.67, suggesting a potential upside of 85.94%. Relay Therapeutics has a consensus price target of $22.20, suggesting a potential upside of 234.34%. Given Mesoblast's stronger consensus rating and higher probable upside, analysts clearly believe Relay Therapeutics is more favorable than Mesoblast.
Summary
Mesoblast beats Relay Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Relay Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relay Therapeutics Competitors List
Related Companies and Tools
